Comorbidities are independently associated with worsened physical function among patients with psoriatic arthritis (PsA), according to the findings of a recent study.
The cross-sectional analysis included 738 participants with ankylosing spondylitis (AS) and 721 participants with PsA who were involved in the CARMA study. Overall, 21% of participants had more than 1 comorbidity.
You may also like...
Early TNFi Initiation Nearly Doubles PsA Remission Rates
‘Green Nail’ in Imaging a Potential Sign for PsA
A proxy for the Charlson Comorbidity Index (CCIp), sociodemographic data, disease activity, disease duration, radiographic damage, and treatment were included as independent variables. Physical function was the dependent variable in multivariate models.
Analysis showed that comorbidity burden determined by CCIp was independently associated with worsened adjusted physical function among participants with PsA. Worsened function among those with PsA was also associated with female sex, disease duration, disease activity, nonsteroidal anti-inflammatory drugs, glucocorticoids, and biologics. However, a higher educational level was associated with less disability.
Among participants with AS, age, disease activity, radiographic damage, and biologics were independently associated with worsened function, but not CCIp.
The detection and control of the comorbidities may be integral part of managing PsA, the researchers concluded.
Fernández‐Carballido C, Martín‐Martínez MA, García‐Gómez C, et al. Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics. Results from the CARdiovascular in rheuMAtology (CARMA) study [published online April 29, 2019]. Arthritis Care Res. doi:10.1002/acr.23910